Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma

Haematologica

Volumn 97, Issue 2, 2012, Pages 262-269

  Porrata, Luis F ^a   Ristow, Kay ^a   Colgan, Joseph P ^a   Habermann, Thomas M ^a   Witzig, Thomas E ^a   Inwards, David J ^a   Ansell, Stephen M ^a   Micallef, Ivana N ^a   Johnston, Patrick B ^a   Nowakowski, Grzegorz S ^a   Thompson, Carrie ^a   Markovic, Svetomir N ^a  

^a MAYO CLINIC   (United States)

Author keywords

Absolute lymphocyte count; Absolute monocyte count; Biomarker; Classical hodgkin's lymphoma; Prognosis; Ratio

Indexed keywords

BLEOMYCIN; CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLASSICAL HODGKIN LYMPHOMA; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOCYTE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL LYMPHOCYTE; PROGNOSIS; PROGRESSION FREE SURVIVAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HODGKIN DISEASE; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; MONOCYTES; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84856446578     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.050138     Document Type: Article

References (22)

1. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. N Engl J Med. 1998;339(21):1506-14.
2. Colby TV, Hoppe RT, Warnke RA. Hodgkin's disease: a clinicopathologic study of 659 cases. Cancer. 1981;49(9): 1848-58.
3. Schreck S, Friebel D, Buettner M, Distel L, Grabenbauer G, Young LS, et al. Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lym-phoma. Hematol Oncol. 2009; 27(1):31-9.
4. Alvaro-Naranjo T, Lejeune M, Salvado-Usach MT, Bosch-Princep R, Reverter-Branchat G, Jaen-Martinez G, et al. Tumor-infiltrating cells as a prognostic factor in Hodgkin's lymphoma: a quantitative tissue microarray study in a large retrospective cohort of 267 patients. Leuk Lymphoma. 2005; 46 (11):1581-91.
5. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, et al. Tumor-associated macrophages and survival in classic Hodg -kin's lymphoma. N Engl J Med. 2010; 362(10):875-85.
6. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351 (21):2159-69.
7. Shivakumar L, Ansell S. Targeting B-lym-phocyte stimulator/B-cell activating factor and a proliferation-inducing ligand in hema-tologic malignancies. Clin Lymphoma Myeloma. 2006; 7(2):106-8.
8. Wilcox RA, Wada DA, Ziesmer SC, Elsawa SF, Comfere NI, Dietz AB, et al. Monocytes promote tumor cell survival in T-cell lym-phoproliferative disorders and are impaired in their ability to differentiate into mature dendritic sells. Blood. 2009; 114(4):2936-44.
9. Lamagna C, Aurrand L.M, Lmhot BA. Dual role of macrophages in tumor growth and angiogenesis. J Leukoc Biol. 2006;80 (4):705-13.
10. Ribatti D, Nico B, Crivellato E, Vacca A. Macrophages and tumor angiogenesis. Leukemia. 2007;21(10):2085-9.
11. Green CE, Liu T, Montel V, Hsiao G, Lester RD, Subramaniam S, et al. Chemoattractant signaling between tumor cells and macrophages regulates cancer cell migration, metastasis, and neovascularization. PLoS One. 2009;4(8):e6713.
12. Roca H, Varsos ZS, Sud S, Craig MJ, Ying C, Piena KJ. CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem. 2009; 284(49):34342-54.
13. Dirkx AE, Oude Egbrink MG, Wagstaff J, Griffioen AW. Monocyte/macrophages infiltration in tumors: modulators of angiogene-sis. J Leukoc Biol. 2006; 80 (6):1183-96.
14. Gandhi MK, Lambley E, Duraiswamy J, Dua U, Smith C, Elliott S, et al. Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients. Blood. 2006;108(7):2280-9.
15. Fozza C, Longinotti M. T-cell traffic jam in Hodgkin's lymphoma: pathogenetic and therapeutic implications. Adv Hematol. 2011;2011:501659.
16. Donskov F, Bennedsgaard KM, von der Maase H, Marcussen N, Fisker R, Jensen JJ, et al. Intratumoral and peripheral blood lymphocytes subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival. Br J Cancer. 2002;87(2):194-201.
17. Cox CJ, Haberman TM, Payne BA, Klee GG, Pierre RV. Evaluation of the Coulter counter model S-Plus IV. Am J Clin Pathol. 1985; 84(3):297-306.
18. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lym-phoma. J Clin Oncol. 2007;25(5):579-86.
19. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-81.
20. Cox DR. Regression models and life-tables. J R Stat Soc (B). 1972;34:187-202.
21. Tzankov A, Zlobec I, Went P, Robl H, Hoeller S, Dirnhofer S. Prognostic immuno -phenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores. Leuk Lymphoma. 2010;51(2):199-212.
22. Kohave R. A study of cross-validation and bootstrap for accuracy estimation and model selection. International Joint Conference on Artificial Intelligence (IJCAI). 1995: 1137-45.